Stockscreener 앱 받기
10.84
0.37%
-0.04
시간 외 거래:
10.84
전일 마감가:
$10.88
열려 있는:
$10.58
하루 거래량:
389.17K
Relative Volume:
1.98
시가총액:
$488.43M
수익:
-
순이익/손실:
$-32.74M
주가수익비율:
-6.8966
EPS:
-1.5718
순현금흐름:
$-24.89M
1주 성능:
-3.73%
1개월 성능:
-6.71%
6개월 성능:
-12.16%
1년 성능:
+1.69%
1일 변동 폭
$10.40
$11.19
1주일 범위
$10.40
$11.88
52주 변동 폭
$8.075
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
명칭
Third Harmonic Bio Inc
전화
(209) 727-2457
주소
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
10.84 | 488.43M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-07 | 개시 | Raymond James | Outperform |
| 2022-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 개시 | Cowen | Outperform |
| 2022-10-10 | 개시 | Jefferies | Buy |
| 2022-10-10 | 개시 | Morgan Stanley | Overweight |
모두보기
Third Harmonic Bio Inc 주식(THRD)의 최신 뉴스
Long Term Trading Analysis for (THRD) - Stock Traders Daily
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa
Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance
How the (THRD) price action is used to our Advantage - Stock Traders Daily
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com
Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN
(THRD) Technical Pivots with Risk Controls - Stock Traders Daily
RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com
Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com
Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN
Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN
Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks
Third Harmonic Bio Inc (THRD) Quarterly 10-Q Report - Quartzy
Third Harmonic Bio (THRD) to Present at Major Stifel, Jefferies Healthcare Conferences | THRD Stock News - StockTitan
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Third Harmonic Flat on Q3 Results - Baystreet.ca
Third Harmonic Bio Announces Third Quarter 2024 Financial Results - The Manila Times
Third Harmonic Bio Reports $296M Cash Position, Phase 1 Trial Progress Despite Wider Q3 Loss | THRD Stock News - StockTitan
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
(THRD) Technical Data - Stock Traders Daily
Third harmonic bio sees $14.3 million in stock sales by BVF Partners - Investing.com India
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
Third Harmonic Bio's chief medical officer sells $40,095 in stock - Investing.com
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Down -18.64% in 4 Weeks, Here's Why Philips (PHG) Looks Ripe for a Turnaround - MSN
Harmonic Announces Third Quarter 2024 Results - Yahoo Finance
Where are the Opportunities in (THRD) - Stock Traders Daily
Harmonic Discovery presents FLT3 kinase inhibitor with enhanced safety profile - BioWorld Online
Revvity Earnings Preview: What to Expect - MSN
Forbion follows string of startup exits with $2.2B fundraise - BioPharma Dive
(THRD) Trading Signals - Stock Traders Daily
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug - BioPharma Dive
Startup led by John Maraganore raises $135M to build ‘future of RNAi’ - BioPharma Dive
Third Harmonic Bio: Nothing Stands Out (NASDAQ:THRD) - Seeking Alpha
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney - BioPharma Dive
How To Trade (THRD) - Stock Traders Daily
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise By Investing.com - Investing.com South Africa
WAVE Life Sciences (NASDAQ:WVE) Stock Quotes, Forecast and News Summary - Benzinga
Third Harmonic Bio executive sells shares worth over $71,000 - Investing.com India
Third harmonic bio executive sells over $140k in stock By Investing.com - Investing.com South Africa
Third Harmonic Bio executive sells shares worth over $71,000 By Investing.com - Investing.com Australia
Third harmonic bio executive sells over $140k in stock - Investing.com
Third Harmonic Bio Inc (THRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Third Harmonic Bio Inc 주식 (THRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
2.88%
2.65%
자본화:
|
볼륨(24시간):